Amarin Announces Notification of Patent Allowance for Vascepa in US
Amarin Corporation plc (Nasdaq: AMRN), announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 13/282,145, titled "Method of Treating Hypertriglyceridemia." The application includes claims intended to protect the Vascepa indication approved in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.